Twist Bioscience TWST 深 滬
等待開盤 01-14 09:30:00 美东时间
40.506
+2.466
+6.48%
華盛通- 最 高40.52
- 今 開38.63
- 成交量 79.78万股
- 最 低 38.1051
- 昨 收 38.04
- 總市值 24.77亿
- 52周最高 54.74
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 23.30
- 委 比 -90.24%
- 總股本 6114.80万
- 歷史最高 214.07
- 量 比 1.11
- 振 幅 6.35%
- 歷史最低 11.46
- 每 手 1
- 風險率 6.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 200 points on M...
01-12 23:07
Twist Bioscience Affirms FY2026 Sales Guidance of $425.000M-$435.000M vs $430.837M Est
Twist Bioscience (NASDAQ:TWST) affirms FY2026 sales outlook from $425.000 million-$435.000 million to $425.000 million-$435.000 million vs $430.837 million estimate.
01-12 21:42
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $43
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $32 to $43.
01-09 02:21
夜读 | 2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技！
2026年美股该如何操作？“木头姐”最新战略揭晓：押注基因编辑，抛售消费科技，特斯拉仍为最大持仓！布局详情>>
01-05 23:59
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in Tesla (TSLA) and space-launch operator Rocket Lab (RKLB). Ark load...
2025-12-29 21:15
Aptamer Group Partners with Twist Bioscience for NGS Market Expansion
Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group plc has ...
2025-12-16 18:37
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $39
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $37 to $39.
2025-12-16 05:11
